BETHESDA, Md., April 10, 2012 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – would like to remind investors and analysts that the management will host a conference call to provide a business update and answer questions tomorrow, April 11, 2012 beginning at 1:00 p.m. Eastern time. During the call management will review the Company's 2011 financial results, and provide an update on its development progress, including work with SPX-106T.
Last year Spherix undertook an asset-centric growth strategy based on SPX-106T, and is now launching a combination-drug discovery platform based on a dynamic data-driven application simulation (DDDAS) approach. In addition to its own combination drugs, Spherix is looking at Phase 1 and Phase 2 assets to roll-up in this platform. The DDDAS program began at the National Science Foundation and is now being employed to model complex metabolic disease pathways, test potential binary therapies in simulations of various combinations and choose the most effective pair-wise combinations. DDDAS is being deployed in animal and human studies planned by Spherix.
To access the conference call, from the U.S. please dial (866) 322-1352 and from outside the U.S. please dial (706) 643-6246. All listeners should provide the following passcode: 62805777. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website, www.spherix.com.
Following the end of the conference call, a telephone replay will be available through April 17, 2012, and can be accessed by dialing (855) 859-2056 from the U.S. or (404) 537-3406 from outside of the U.S. All listeners should provide the following passcode: 62805777. The webcast will be available for 30 days.
Reminder: Spherix To Hold Business Update Conference Call April 11 At 1:00 P.m. Eastern Time
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts